Greenwich LifeSciences, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Greenwich LifeSciences, Inc. (GLSI), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are GLSI insiders buying or selling?
In the last 12 months, Greenwich LifeSciences, Inc. insiders reported 11 open-market purchases ($586.3K) and 0 sales ($0) — net buying of $586.3K. Since September 2020, Trabud has recorded 116 Form 4 filings for GLSI: 116 buys ($8.1M) and 0 sells ($0).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $91.8K by Snehal Patel (CEO and CFO) on Jan 5, 2026. SEC ↗
- The most recent open-market purchase was reported on Jul 30, 2026 (2 months ago).
Key Statistics (September 2020 – Jul 30, 2026)
Total Form 4 filings
116
SEC EDGAR
Insider filers
6
Insider buys (116)
$8.1M
Insider sells (0)
$0
Insider sentiment
Net buyingNet insider flow of $8.1M in net buying since September 2020, and $586.3K in net buying over the last 12 months. 3 insider buys in the last 90 days.
Recent GLSI insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | Snehal Patel | CEO and CFO | Purchase | 2.2K | $13.43 | $29.6K | SEC ↗ |
| Jul 29, 2026 | Snehal Patel | CEO and CFO | Purchase | 1.5K | $13.62 | $20.4K | SEC ↗ |
| Jul 27, 2026 | Snehal Patel | CEO and CFO | Purchase | 3.6K | $13.06 | $47.0K | SEC ↗ |
| Jan 15, 2026 | Snehal Patel | CEO and CFO | Purchase | 1.8K | $29.83 | $53.7K | SEC ↗ |
| Jan 14, 2026 | Snehal Patel | CEO and CFO | Purchase | 2.9K | $27.54 | $79.9K | SEC ↗ |
| Jan 5, 2026 | Snehal Patel | CEO and CFO | Purchase | 4.3K | $21.36 | $91.8K | SEC ↗ |
| Jan 2, 2026 | Snehal Patel | CEO and CFO | Purchase | 2.9K | $21.73 | $63.0K | SEC ↗ |
| Dec 19, 2025 | Snehal Patel | CEO and CFO | Purchase | 4.1K | $12.62 | $51.7K | SEC ↗ |
| Nov 28, 2025 | Snehal Patel | CEO and CFO | Purchase | 4.6K | $8.37 | $38.5K | SEC ↗ |
| Nov 12, 2025 | Snehal Patel | CEO and CFO | Purchase | 10.6K | $8.43 | $89.4K | SEC ↗ |
| Nov 4, 2025 | Snehal Patel | CEO and CFO | Purchase | 2.3K | $9.26 | $21.3K | SEC ↗ |
| Apr 29, 2025 | Snehal Patel | CEO and CFO | Purchase | 3.6K | $9.88 | $35.6K | SEC ↗ |
| Apr 22, 2025 | Snehal Patel | CEO and CFO | Purchase | 5.4K | $8.98 | $48.5K | SEC ↗ |
| Apr 8, 2025 | Snehal Patel | CEO and CFO | Purchase | 3.6K | $9.10 | $32.8K | SEC ↗ |
| Apr 7, 2025 | Snehal Patel | CEO and CFO | Purchase | 5.5K | $8.73 | $48.0K | SEC ↗ |
| Jan 13, 2025 | Snehal Patel | CEO and CFO | Purchase | 2.5K | $12.51 | $31.3K | SEC ↗ |
| Jan 8, 2025 | Snehal Patel | CEO and CFO | Purchase | 2.9K | $13.58 | $39.4K | SEC ↗ |
| Jan 7, 2025 | Snehal Patel | CEO and CFO | Purchase | 3.4K | $12.95 | $44.0K | SEC ↗ |
| Jan 6, 2025 | Snehal Patel | CEO and CFO | Purchase | 2.0K | $11.97 | $23.9K | SEC ↗ |
| Jan 3, 2025 | Snehal Patel | CEO and CFO | Purchase | 2.4K | $11.36 | $27.3K | SEC ↗ |
| Jan 2, 2025 | Snehal Patel | CEO and CFO | Purchase | 3.2K | $11.12 | $35.6K | SEC ↗ |
| Nov 25, 2024 | Jaye Thompson | VP Clinical Reg Affairs | Purchase | 1.0K | $12.91 | $12.9K | SEC ↗ |
| Sep 30, 2024 | Snehal Patel | CEO and CFO | Purchase | 1.5K | $14.63 | $21.9K | SEC ↗ |
| Sep 16, 2024 | Jaye Thompson | VP Clinical Reg Affairs | Purchase | 800 | $13.85 | $11.1K | SEC ↗ |
| Aug 8, 2024 | Snehal Patel | CEO and CFO | Purchase | 2.0K | $13.81 | $27.6K | SEC ↗ |
Showing the 25 most recent of 116 Form 4 filings for Greenwich LifeSciences, Inc..
Most active GLSI insiders
- Snehal Patel82 filings
- Jaye Thompson21 filings
- Kenneth Hallock5 filings
- Frank Joseph Daugherty4 filings
- McWilliams David3 filings
Ask anything about GLSI insider activity
Use Trabud's AI agent to query Greenwich LifeSciences, Inc.'s Form 4 history in plain English — "Show me GLSI CEO purchases this year" or compare it against any other ticker.
Open the AI agentGLSI insider trading FAQ
Are Greenwich LifeSciences, Inc. insiders buying or selling?
In the last 12 months, Greenwich LifeSciences, Inc. insiders reported 11 open-market purchases ($586.3K) and 0 sales ($0) — net buying of $586.3K. Since September 2020, Trabud has recorded 116 Form 4 filings for GLSI: 116 buys ($8.1M) and 0 sells ($0). Over the full record that is net buying of $8.1M.
How many insiders trade GLSI stock?
6 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Greenwich LifeSciences, Inc.. The most recent filing was accepted on Jul 30, 2026.
Where does Trabud get GLSI insider trading data?
All GLSI insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.